Oncology Imaging

Medical imaging has become integral to cancer care, assessing the stage and location of cancerous tumors. By utilizing powerful imaging modalities including CT, MRI, MRA and PET/CT, oncology imaging radiologists are able to assist referring physicians in the detection and diagnosis of cancer.

IBA takes stake in PET Net Germany

Ion Beam Applications (IBA) has taken a minority stake acquisition in PET Net and PET Net Solutions, providers of PET radiopharmaceuticals to nuclear medicine facilities throughout Germany.

Morphotek acquires tumor targeting assets from TransMolecular

Eisais U.S. subsidiary Morphotek has acquired certain assets relating to a proprietary tumor targeting platform from TransMolecular.

Caliper Life Sciences launches COX-2 probe

Caliper Life Sciences has launched XenoLight RediJect COX-2 Probe (Fluorocoxibs), a fluorescent imaging agent for preclinical research that specifically detects the cyclooxygenase-2 (COX-2) biomarker noninvasively in live animal models as well as in ex vivo tissue analysis applications.

Feature: Intraoperative breast RT in practice

Nearly one year after initial findings indicated that intraoperative single-dose radiation is as effective as whole-breast radiation therapy in limiting recurrence of breast cancer in selected patients, physicians at Northwestern Memorial Hospital in Chicago are offering the condensed treatment to a select group of patients.

NEJM: CER savings close to $1B, if practice changes

As physicians and policymakers gear up for healthcare reform and the elusive goal of improved outcomes at lower costs, providers and payors are increasingly looking to comparative effectiveness research to guide clinical practice and reimbursements, evidenced by a solid investment on the part of the government, argued the authors of a perspective article in the New England Journal of Medicine.

FDA clears MIM Symphony for brachytherapy

MIM Softwares MIM Symphony is available as a brachytherapy treatment planning system for permanent seed implants.

JCO: Active surveillance reasonable for low-risk prostate cancer

Out of a total of 769 men with prostate cancer who opted for active surveillance in lieu of treatment, nearly half did not require any treatment within 15 years, and no patients died from the disease, a study published online in the Journal of Clinical Oncology reported.

Novelos Therapeutics acquires Cellectar

Novelos Therapeutics has completed its acquisition of Cellectar and $5.1 million financing to develop three novel cancer-targeted compounds.

Around the web

GE HealthCare designed the new-look Revolution Vibe CT scanner to help hospitals and health systems embrace CCTA and improve overall efficiency.

Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.

The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.